Literature DB >> 1847221

Absorbable mesh splenorrhaphy for severe splenic injuries: functional studies in an animal model and an additional patient series.

F B Rogers1, N E Baumgartner, A P Robin, J A Barrett.   

Abstract

Polyglycolic acid mesh has been introduced as a method of controlling hemorrhage in severely damaged spleens. This study examines the effect of splenic wrapping on the immune function of the spleen, and also on its ability to control splenic bleeding in trauma patients. Thirty purebred beagle dogs were divided into three groups and subjected to sham operation (Group 1), splenectomy (Group 2), and splenic wrap (Group 3). Immunologic studies showed no difference between the wrapped group (Group 3) and those with their spleens intact (Group 1) in the induction of specific antibody-producing lymphocytes in splenic tissue after the injection of attenuated Pneumococci. All splenic injuries treated at Cook County Hospital between January 1985 and May 1988 were retrospectively analyzed. Of 60 patients with splenic injuries, 14 underwent mesh splenorrhaphy without mortality or serious complications. This study demonstrates that the immune function of spleen is preserved following mesh splenorrhapy, and that this technique can be used in a clinical setting with safe and efficacious results.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847221

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  3 in total

1.  [Therapy of splenic injuries by freezing and fibrin gluing. Animal experiment study].

Authors:  M Vatankhah; K O Möller; B M Lind; G Baretton
Journal:  Langenbecks Arch Chir       Date:  1992

Review 2.  Continuing evolution in the approach to severe liver trauma.

Authors:  R L Reed; R C Merrell; W C Meyers; R P Fischer
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

3.  Imaging findings of implanted absorbable mesh in patients with breast partial resection.

Authors:  Hyon Joo Kwag
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.